Data Integrity in Pharmaceutical Laboratories: A Systematic Review of Regulatory Expectations and Quality Practices
Annales Pharmaceutiques Françaises · 2026-11
DOI: 10.1016/j.pharma.2026.11.003 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Annales Pharmaceutiques Françaises, 2026-11. Verfasst von Meryem Chennaq und 4 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco; Ibn Sina University Hospital Center, 10 170 Rabat, Morocco. Electronic addre….
Abstract (Originalsprache)
BACKGROUND: Data integrity (DI) has become a central pillar of pharmaceutical quality assurance and a recurrent focus of regulatory inspections worldwide. Despite mature guidance, DI deficiencies remain among the most frequently cited inspection observations in good-practice (GxP) environments. This systematic review aimed to identify, analyse and synthesise the regulatory expectations and quality practices governing DI in pharmaceutical laboratories. METHODS: Following the PRISMA 2020 framework, scientific databases and regulatory repositories (FDA, EMA, MHRA, WHO, PIC/S), together with authoritative technical sources, were searched for publications issued between 2002 and 2025. Records were screened in two stages against predefined criteria, and retained studies analysed through structured narrative synthesis. Seventy-six studies were included. RESULTS: Studies converged on four domains: (i) regulatory frameworks and DI governance, built on ALCOA/ALCOA+ principles and a convergent cross-jurisdictional stance; (ii) operational laboratory practices and risk factors, with quality control laboratories the most vulnerable; (iii) digital transformation and Pharma 4.0 technologies, including validated computerised systems, cloud, artificial intelligence and blockchain; and (iv) violations and organisational determinants, where weak quality culture and inadequate oversight emerged as decisive root causes. CONCLUSION: DI is not solely technical or documentary but a systemic, cultural attribute of the quality system, requiring governance, risk-based controls, validated infrastructure and leadership commitment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco; Ibn Sina University Hospital Center, 10 170 Rabat, Morocco. Electronic address: Meryemchennaq12@gmail.com.
- Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco; Ibn Sina University Hospital Center, 10 170 Rabat, Morocco. Electronic address: sulikoialare@gmail.com.
- Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco; Ibn Sina University Hospital Center, 10 170 Rabat, Morocco; Team of Formulation and Quality Control of Health Products, Faculty of Medicine and Ph…
- Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco; International University of Rabat- UIR, Morocco. Electronic address: ihsane.hmamouchi@uir.ac.ma.
Zitieren
APA
Chennaq, M., Lare, S., Aliat, Z., Hmamouchi, I., & Rahali, Y. (2026). Data Integrity in Pharmaceutical Laboratories: A Systematic Review of Regulatory Expectations and Quality Practices. Annales Pharmaceutiques Françaises. https://doi.org/10.1016/j.pharma.2026.11.003
Vancouver
Chennaq M, Lare S, Aliat Z, Hmamouchi I, Rahali Y. Data Integrity in Pharmaceutical Laboratories: A Systematic Review of Regulatory Expectations and Quality Practices. Annales Pharmaceutiques Françaises. 2026. doi:10.1016/j.pharma.2026.11.003
BibTeX
@article{Chennaq2026,
author = {Chennaq, Meryem and Lare, Sulikoia and Aliat, Zineb and Hmamouchi, Ihsane and Rahali, Younes},
title = {Data Integrity in Pharmaceutical Laboratories: A Systematic Review of Regulatory Expectations and Quality Practices},
journal = {Annales Pharmaceutiques Françaises},
year = {2026},
doi = {10.1016/j.pharma.2026.11.003}
}
EUVIMED